Real-World Semaglutide Use Shows Benefits for Type 2 Diabetes with Kidney Failure

Managing Type 2 diabetes (T2D) in patients with end-stage renal disease (ESRD) is exceptionally challenging due to complex drug metabolism, increased comorbidity burden, and a heightened risk of adverse events. Current clinical guidelines often lack robust evidence for specific therapeutic strategies in this vulnerable population, leaving a significant treatment gap. This study addresses the crucial need for real-world data on the efficacy and safety of semaglutide in patients with both type 2 diabetes and end-stage renal disease.

The comprehensive analysis revealed significant improvements in both glycemic control and body weight among the ESRD patients receiving semaglutide. Mean HbA1c levels demonstrated a substantial decrease of 1.1% (from a baseline of 8.3% to 7.2%, p<0.001) after 12 months of continuous treatment. Concurrently, patients experienced an average body weight reduction of 6.2 kg (p<0.001), with a notable 38% of the cohort achieving a clinically significant weight loss of >5% from their baseline. The most important finding was that semaglutide demonstrated a favorable safety profile in this high-risk population, with no unexpected renal adverse events and a remarkably low incidence of severe hypoglycemia (<1%). Gastrointestinal side effects, predominantly nausea and diarrhea, were reported in 18% of patients, a rate consistent with observations in the general T2D population, and led to treatment discontinuation in only 5%. Furthermore, semaglutide treatment was associated with a 25% reduction in the rate of hospitalizations for cardiovascular events compared to the 12 months prior to initiation (p=0.03).